Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allarity Therapeutics (ALLR) Net Cash Flow (2024 - 2025)

Allarity Therapeutics' Net Cash Flow history spans 2 years, with the latest figure at -$3.5 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 438.48% year-over-year to -$3.5 million; the TTM value through Dec 2025 reached -$4.2 million, down 121.46%, while the annual FY2025 figure was -$4.2 million, 121.84% down from the prior year.
  • Net Cash Flow reached -$3.5 million in Q4 2025 per ALLR's latest filing, down from -$1.1 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $19.0 million in Q2 2024 to a low of -$8.0 million in Q2 2025.